642.80
+10.20
+(1.61%)
At close: January 31 at 3:30:34 PM GMT+1
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | -- | -- | -- | -- |
| Avg. Estimate | 0 | 0 | 0 | 0 |
| Low Estimate | 0 | 0 | 0 | 0 |
| High Estimate | 0 | 0 | 0 | 0 |
| Year Ago EPS | -- | -- | -- | -- |
Revenue Estimate
| Currency in EUR | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 19 | 10 | 26 | 28 |
| Avg. Estimate | 677.26M | 707.56M | 2.08B | 3.13B |
| Low Estimate | 538.06M | 650.48M | 1.96B | 2.21B |
| High Estimate | 737.2M | 777.36M | 2.19B | 3.73B |
| Year Ago Sales | 385.67M | 383.84M | 1.17B | 2.08B |
| Sales Growth (year/est) | 75.61% | 84.34% | 77.79% | 50.36% |
EPS Trend
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | 0 | 0 | 0 | 0 |
| 7 Days Ago | 0 | 0 | 0 | 0 |
| 30 Days Ago | 0 | 0 | 0 | 0 |
| 60 Days Ago | 0 | 0 | 0 | 0 |
| 90 Days Ago | 0 | 0 | 0 | 0 |
EPS Revisions
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| ARGX.VI | -- | -- | -- | -- |
| S&P 500 | 9.91% | 10.33% | 14.01% | 13.75% |
Related Tickers
4DN.F Denali Therapeutics Inc.
22.59
+0.89%
22Z.F Zealand Pharma A/S
99.60
+2.57%
TRGNF Transgene SA
1.5900
0.00%
UNC.MU UCB SA
188.20
-0.74%
ABVX.PA ABIVAX Société Anonyme
6.04
+2.90%
GNTA Genenta Science S.p.A.
3.5200
-15.18%
NWRN.SW Newron Pharmaceuticals S.p.A.
9.46
+0.42%
IDIA.SW Idorsia Ltd
0.7040
-1.61%
SANN.SW Santhera Pharmaceuticals Holding AG
17.12
+4.39%
SPRO Spero Therapeutics, Inc.
0.8566
-1.54%